A phase II trial of induction gemcitabine and vinorelbine followed by concurrent vinorelbine and radiotherapy in locally advanced non-small cell lung cancer

Lung Cancer

Volumn 67, Issue 3, 2010, Pages 325-329

  Leong, Swan Swan ^a   Fong, Kam Weng ^a   Lim, Wan Teck ^a   Toh, Chee Keong ^a   Yap, Swee Peng ^a   Hee, Siew Wan ^a   Tan, Eng Huat ^a  

^a DIVISION OF MEDICAL ONCOLOGY   (Singapore)

Author keywords

Chemo radiotherapy; Gemcitabine; Locally advanced; Lung cancer; Non platinum; Vinorelbine

Indexed keywords

GEMCITABINE; NAVELBINE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG FATALITY; DRUG TOLERABILITY; ESOPHAGITIS; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; LUNG EMBOLISM; LUNG NON SMALL CELL CANCER; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; NEUTROPENIA; NEUTROPHIL; ODYNOPHAGIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RADIATION DOSE; RECURRENT DISEASE; SIDE EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR VOLUME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; REMISSION INDUCTION; VINBLASTINE;

EID: 75749142638     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2009.04.022     Document Type: Article

References (36)

1. Roth J.A., Fossella F., Komaki R., Ryan M.B., Putnam Jr. J.B., Lee J.S., et al. A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. J Natl Cancer Inst 86 9 (1994) 673-680
2. Rosell R., Gomez-Codina J., Camps C., Maestre J., PadilleJ, Canto A., et al. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. N Engl J Med 330 (1994) 153-158
3. Jeremic B., Shibamoto Y., Acimovic L., and Djuric L. Randomized trial of hyperfractionated radiation therapy with or without concurrent chemotherapy for stage III non-small-cell lung cancer. J Clin Oncol 13 (1995) 452-458
4. Schaake-Koning C., Van Den Bogaert W., Dalesio O., Festen J., Hoogenhout J., Van Houtte P., et al. Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N Engl J Med 326 (1992) 524-530
5. Furuse K., Fukuoka M., Kawahara M., Nishikawa H., Takada Y., Kudoh S., et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 17 9 (1999) 2692-2699
6. Anderson H., Lund B., Bach F., Thatcher N., Walling J., and Hansen H.H. Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: a phase II study. J Clin Oncol 9 12 (1994) 1821-1826
7. Gatzemeier U., Shepherd F.A., Le Chevalier T., Weynants P., Cottier B., Groen H.J., et al. Activity of gemcitabine in patients with non-small cell lung cancer: a multicentre, extended phase II study. Eur J Cancer 2 32A (1996) 243-248
8. Sandler A.B., Nemunaitis J., Denham C., Von Pawel J., Cormier Y., Gatzemeier U., et al. Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 18 1 (2000) 122-130
9. Depierre A., Lemarie E., Dabouis G., Garnier G., Jacoulet P., and Dalphin J.C. A phase II study of navelbine (vinorelbine) in the treatment of non-small-cell lung cancer. Am J Clin Oncol 14 (1991) 115-119
10. Le Chevalier T., Brisgand D., Douillard J.Y., Pujol J.L., Alberola V., Monnier A., et al. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell-lung cancer: results of a European multicenter trial including 612 patients. J Clin Oncol 12 (1994) 360-367
11. Laack E., Mende T., Benk J., Chemaissani A., ScholtzeJ, Lorenz C., et al. Gemcitabine and vinorelbine as first-line chemotherapy for advanced non-small cell lung cancer: a phase II trial. Eur J Cancer 37 5 (2001) 583-590
12. Lilenbaum R. Options in advanced non-small cell lung cancer: a review and report on a phase II study of vinorelbine plus gemcitabine. Oncologist 6 Suppl. 1 (2001) 16-19
13. Baron F., Cueva J., Grana B., Curiel T., Leon L., Vazquez F., et al. Gemcitabine plus vinorelbine for the treatment of advanced non-small cell lung cancer. Eur J Cancer 37 11 (2001) 1381-1384
14. Gridelli C., Frontini L., Perrone F., Gallo C., Gulisano M., Cigolari S., et al. Gemcitabine plus vinorelbine in advanced non-small cell lung cancer: a phase II study of three different doses. Gem Vin Investigators. Br J Cancer 83 6 (2000) 707-714
15. Palmeri S., Leonardi V., Gebbia V., De Bella M.T., Ferrau F., Faillu G., et al. Gemcitabine plus vinorelbine in stage IIIB or IV non-small cell lung cancer (NSCLC): a multicentre phase II clinical trial. Lung Cancer 34 1 (2001) 115-123
16. Tan E.H., Szczesna A., Krzakowski M., Macha H.N., Gatzemeier U., Mattson K., et al. GLOBE 2 group Randomized study of vinorelbine-gemcitabine versus vinorelbine-carboplatin in patients with advanced non-small cell lung cancer. Lung Cancer 49 (2005) 233-240
17. Gridelli C., Guida C., Barletta E., Gatani T., Fiore F., Barzelloni M.L., et al. Thoracic radiotherapy and daily vinorelbine as radiosensitizer in locally advanced non small cell lung cancer: a phase I study. Lung Cancer 29 (2000) 131-137
18. Garst J., Shafman T., Campagna L., and Herndon J. A phase II study of concurrent multidose vinorelbine with definitive radiation therapy for inoperable stage III non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 20 1 (2001) 343a
19. Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L., et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92 (2000) 201-216
20. Kaplan E.L., and Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 53 (1958) 457-481
21. Sandler A., Gray R., Perry M.C., Brahmer J., Schiller J.H., Dowlati A., et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell-lung cancer. N Engl J Med 355 (2006) 2542-2550
22. Pirker R., Szczesna A., Von Pawel J., Kczakowski M., Ramlau R., Park K., et al. FLEX: a randomized, multicenter, phase III study of cetuximab in combination with cisplatin/vinorelbine (CV) versus CV alone in the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC). Proc Am Soc of Clin Oncol 26 (2008) 3
23. Hida T., Okamoto I., Kashii T., Satouchi M., Ichinose Y., Katakami N., et al. Randomized phase III study of platinum-doublet chemotherapy followed by gefitinib versus continued platinum-doublet chemotherapy in patients with advanced non-small cell lung cancer (NSCLC): results of West Japan Thoracic Oncology Group trial (WJTOG). Proc Am Soc Clin Oncol 26 (2008) LBA8012
24. Kelly K., Chansky K., Gaspar L.E., Albain K.S., Jett J., Ung Y.C., et al. Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in operable stage III non-small-cell lung cancer: SWOG S0023. J Clin Oncol 26 (2008) 2450-2456
25. Stinchcombe T.E., Morris D.E., Lee C.B., Moore D.T., Hayes D.N., Halle J.S., et al. Induction chemotherapy with carboplatin, irinotecan, and paclitaxel followed by high dose three-dimension conformal thoracic radiotherapy (74 Gy) with concurrent carboplatin, paclitaxel, and gefitinib in unresectable stage IIIA and stage IIIB non-small cell lung cancer. J Thorac Oncol 3 (2008) 250-257
26. Vokes E.E., Herndon II J.E., Kelley M.J., Cicchetti M.G., Ramnarh N., Neill H., et al. Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III non-small-cell lung cancer: Cancer and Leukemia Group B. J Clin Oncol 25 (2007) 1698-1704
27. Tell R., Sederholm C., Klintenberg C., Franksson L., Branden E., Hillerdal G., et al. Multicentre phase II trial of paclitaxel and carboplatin with concurrent radiotherapy in locally advanced non-small cell lung cancer. Anticancer Res 28 (2008) 2851-2857
28. Nakamura M., Koizumi T., Hayasaka M., Yasua M., Tsushima K., Kubo K., et al. Cisplatin and weekly docetaxel with concurrent thoracic radiotherapy for locally advanced stage III non-small-cell lung cancer. Cancer Chemother Pharmacol 63 (2009) 1091-1096
29. Pallares C., Capdevila J., Paredes A., Farre N., Ciria J.P., Membrive J., et al. Induction chemotherapy with paclitaxel plus carboplatin followed by paclitaxel with concurrent radiotherapy in stage IIIB non-small-cell lung cancer (NSCLC) patients: a phase II trial. Lung Cancer 58 (2007) 238-245
30. Nyman J., Friesland S., Hallqvist A., Seke M., Bergstrom S., Thaning L., et al. How to improve loco-regional control in stages IIIa-b NSCLC? Results of a three-armed randomized trial from the Swedish Lung Cancer Study Group. Lung Cancer 9 December (2008) [Epub ahead of print]
31. Giorgio C.G., Pappalardo A., Russo A., Santini D., Di Rosa C., Di Salvo C., et al. A phase II study of induction chemotherapy followed by concurrent chemoradiotherapy in elderly patients with locally advanced non-small-cell lung cancer. Anticancer Drugs 18 (2007) 713-719
32. Leong S.S., Tan E.H., Fong K.W., Wilder-Smith E., Ong Y.K., Tai B.C., et al. Randomized double-blind trial of combined modality treatment with or without amifostine in unresectable stage III non-small-cell lung cancer. J Clin Oncol 21 (2003) 1767-1774
33. Movsas B., Scott C., Langer C., Werner-Wasik M., Nicolaou N., Komaki R., et al. Randomized trial of amifostine in locally advanced non-small-cell lung cancer patients receiving chemotherapy and hyperfractionated radiation: radiation therapy oncology group trial 98-01. J Clin Oncol 23 (2005) 2145-2154
34. Hensley M.L., Hagerty K.L., Kewalramani T., Green D.M., Meropol N.J., Wasserman T.H., et al. American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants. J Clin Oncol 27 (2009) 127-145
35. Socinski M.A., Blackstock A.W., Bogart J.A., Wang X., Munley M., Rosenman J., et al. Randomized phase II trial of induction chemotherapy followed by concurrent chemotherapy and dose-escalated thoracic conformal radiotherapy (74 Gy) in stage III non-small-cell lung cancer: CALGB 30105. J Clin Oncol 26 (2008) 2457-2463
36. Leong S.S., Fong K.W., Ong Y.K., Foo K.F., Ang P., Wee J., et al. Chemo-radiotherapy for stage III unresectable non-small cell lung cancer: long-term results of a prospective study. Respir Med 98 (2004) 1080-1086